Telomir Pharmaceuticals, Inc.

Nasdaq:TELO

Pharmaceutical Preparations·MIAMI, FL

CEO

Aminov Erez

CFO

Yanez Michelle

Summary Financials

Revenue

—

Adj. EBITDA

—

Net Income

-$13.1M

FY 2024

EPS (Diluted)

$0.48

FY 2024

Stock Price

$1.32

+3.0%

2026-03-09

52W Range

$1.05 – $5.40

P/E Ratio

2.7x

Market Cap

$45.3M

Cash

$1,231

FY 2024

Total Debt

—

Net Cash

$1,231

Enterprise Value

$45.3M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

Revenue

—

Adj. EBITDA

—

Net Income

-$13.1M

FY 2024

EPS (Diluted)

$0.48

FY 2024

Stock Price

$1.32

+3.0%

2026-03-09

52W Range

$1.05 – $5.40

P/E Ratio

2.7x

Market Cap

$45.3M

Cash

$1,231

FY 2024

Total Debt

—

Net Cash

$1,231

Enterprise Value

$45.3M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—